Methylenedioxymethamphetamine (MDMA)‐related fatal poisoning in Australia, 2016 to 2025: Trends, characteristics and toxicology

Abstract Aims To determine: (1) Population rates of fatal methylenedioxymethamphetamine (MDMA)‐related poisoning over the period 2016–2023, years with high closure rates in the National Coronial Information System (NDIS); (2) the case characteristics of known cases of fatal MDMA‐related poisoning, 2016–2025; and (3) whether there have been changes in case characteristics of known fatal cases in the period pre‐COVID (2016–2019), COVID (2020–2022) and post‐COVID (2023–2025). Design Retrospective study of fatal MDMA‐related poisonings in Australia retrieved from the NDIS, 2016–2025. Setting Australia‐wide. Cases 217 cases of fatal MDMA‐related poisoning. Measurements Population rates, case characteristics, circumstances of death, toxicology, major autopsy findings. Results There was a statistically significant increasing trend in the population rate over 2016–2019 [annual percentage change (APC) = 61.52], and a statistically significant decreasing trend over 2019–2023 (APC = −26.72). The mean age was 33.5 years, and males comprised 170 cases (78.3%). In 179 cases (82.5%) the cause of death was attributed to multiple drug toxicity. The fatal incident occurred in a private setting in 171 cases (78.8%), with 16 (7.4%) occurring at a music festival. The median MDMA blood concentration was 0.41 mg/l (range 0.00–25.0 mg/l). Cases in which death was attributed solely to MDMA toxicity had a higher median MDMA concentration than multiple drug toxicity deaths (1.7 vs. 0.30 mg/l). Psychoactive drugs other than MDMA were detected in 199 cases (91.7%), most commonly other psychostimulants (147, 67.7%) and opioids (98, 45.2%). Cardiomegaly was diagnosed in 33 cases (16.6%) in which the heart was examined, and severe coronary artery disease in 27 (13.6%). There were no statistically significant differences across time periods in age, sex, substance use issues, injecting drug use, intentionality, MDMA concentrations or diagnoses of cardiomegaly. Summary While death rates in Australia from methylenedioxymethamphetamine‐related poisoning have declined from 2019, case characteristics have remained relatively stable.

Authors

Institutions

Publication Details

Journal
Addiction
Published
2026-09-21
DOI
https://doi.org/10.1111/add.70613
Primary Topic
Forensic Toxicology and Drug Analysis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Methylenedioxymethamphetamine (MDMA)‐related fatal poisoning in Australia, 2016 to 2025: Trends, characteristics and toxicology

Johan A Duflou, Amy Peacock, Shane G Darke, Julia Lappin et al.
Addiction
Forensic Toxicology and Drug Analysis
article

Methylenedioxymethamphetamine (MDMA)‐related fatal poisoning in Australia, 2016 to 2025: Trends, characteristics and toxicology

Johan A Duflou, Amy Peacock, Shane G Darke, Julia Lappin, Michael Farrell, Agata Chrzanowska
article en

Abstract

Abstract Aims To determine: (1) Population rates of fatal methylenedioxymethamphetamine (MDMA)‐related poisoning over the period 2016–2023, years with high closure rates in the National Coronial Information System (NDIS); (2) the case characteristics of known cases of fatal MDMA‐related poisoning, 2016–2025; and (3) whether there have been changes in case characteristics of known fatal cases in the period pre‐COVID (2016–2019), COVID (2020–2022) and post‐COVID (2023–2025). Design Retrospective study of fatal MDMA‐related poisonings in Australia retrieved from the NDIS, 2016–2025. Setting Australia‐wide. Cases 217 cases of fatal MDMA‐related poisoning. Measurements Population rates, case characteristics, circumstances of death, toxicology, major autopsy findings. Results There was a statistically significant increasing trend in the population rate over 2016–2019 [annual percentage change (APC) = 61.52], and a statistically significant decreasing trend over 2019–2023 (APC = −26.72). The mean age was 33.5 years, and males comprised 170 cases (78.3%). In 179 cases (82.5%) the cause of death was attributed to multiple drug toxicity. The fatal incident occurred in a private setting in 171 cases (78.8%), with 16 (7.4%) occurring at a music festival. The median MDMA blood concentration was 0.41 mg/l (range 0.00–25.0 mg/l). Cases in which death was attributed solely to MDMA toxicity had a higher median MDMA concentration than multiple drug toxicity deaths (1.7 vs. 0.30 mg/l). Psychoactive drugs other than MDMA were detected in 199 cases (91.7%), most commonly other psychostimulants (147, 67.7%) and opioids (98, 45.2%). Cardiomegaly was diagnosed in 33 cases (16.6%) in which the heart was examined, and severe coronary artery disease in 27 (13.6%). There were no statistically significant differences across time periods in age, sex, substance use issues, injecting drug use, intentionality, MDMA concentrations or diagnoses of cardiomegaly. Summary While death rates in Australia from methylenedioxymethamphetamine‐related poisoning have declined from 2019, case characteristics have remained relatively stable.

Addiction
The University of Sydney (AU), University of Tasmania (AU), Curtin University (AU), UNSW Sydney (AU), National Centre for Clinical Research on Emerging Drugs (AU), National Drug and Alcohol Research Centre (AU), National Drug Research Institute (AU)
Good health and well-being
Openalex Percentile: Top 12%
Forensic Toxicology and Drug Analysis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.